StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias

Recruiting now · Not applicable

Conditions studied: Cardiac Arrhythmia

In brief

This is a prospective, single-center, phase II trial that will be monitoring the safety and efficacy of using stereotactic ablative radiotherapy (SBRT) to treat patients with a medical condition affecting heart rate and rhythm (refractory arrhythmias) within the University Health Network (Princess Margaret Cancer Centre and Toronto General Hospital). The primary objective will be to prospectively monitor patient cardiac outcomes following SBRT.

Key facts

Study ID

NCT04843683

Run by

University Health Network, Toronto

People needed

60

Starts

2021-12-14

Expected to finish

2027-12-01

Last updated by the study team

2026-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with heart rate and rhythm condition (arrhythmia) who have failed standard of care treatment with medication OR at least one prior invasive catheter ablation procedure.
• Patients deemed medically fit to receive stereotactic ablative radiotherapy as determined by their Radiation Oncologist.

You may not qualify if…

• Patients who have previously received high dose radiotherapy to the target area and cannot safely receive further treatment OR are unable to receive radiotherapy due to other contraindications.

Where it is running

• Princess Margaret Cancer Center, University Health Network — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.